文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

比利时某三级医院两波COVID-19疫情期间结局改善

Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium.
PubMed 文献 · Crit Care Explor · 2021-05-19
一句话结论第二波COVID-19疫情中地塞米松使用增加、高流量鼻氧无限制使用及ICU拥挤时转院,与30天死亡率从22%降至15%相关。

该单中心前瞻性队列研究比较了比利时某三级大学医院第一波(2020年3月15日至5月15日)与第二波(2020年10月1日至11月30日)COVID-19住院成人患者的管理与结局。主要终点30天死亡率在第一波为74/341(22%),第二波为98/662(15%)(p=0.007)。第二波病房地塞米松使用(61% vs 3.2%)、高流量鼻氧(12% vs 2%)、瑞德西韦(13.3% vs 0.6%)均增加,羟氯喹使用降至0%,ICU转入率降低(19% vs 26%)。作者认为这些治疗变化与30天死亡率、ICU转入及器官支持减少相关。

要点

  • 30天死亡率:第一波74/341(22%)vs 第二波98/662(15%)(p=0.007)。
  • 病房地塞米松使用:第一波11/341(3.2%)vs 第二波404/662(61%)(p<0.001)。
  • 病房高流量鼻氧:第一波6/341(2%)vs 第二波79/662(12%)(p<0.0001)。
  • ICU转入率:第一波87/341(26%)vs 第二波128/662(19%)(p=0.024)。
  • 第二波33例(4.8%)因ICU拥挤转院并被排除分析。

适用人群与场景

  • 第一波(2020年3月15日至5月15日)或第二波(2020年10月1日至11月30日)入住比利时某三级大学医院的成人COVID-19患者。
  • 第二波因ICU拥挤转院的33例(4.8%)被排除分析。

处置流程与药物剂量

  • 病房地塞米松:第一波11/341(3.2%)vs 第二波404/662(61%)(p<0.001)。
  • 病房高流量鼻氧:第一波6/341(2%)vs 第二波79/662(12%)(p<0.0001)。
  • 病房瑞德西韦:第一波2/341(0.6%)vs 第二波88/662(13.3%)(p<0.0001)。
  • 病房羟氯喹:第一波249/341(73%)vs 第二波0/662(0%)(p<0.0001)。
  • ICU高流量鼻氧:第一波16/87(18%)vs 第二波102/128(80%)(p<0.001)。
  • ICU机械通气:第一波69/87(79%)vs 第二波56/128(44%)(p<0.001),中位持续时间第一波17天(10-26天)vs 第二波10天(5-17天)(p=0.01)。
  • ICU肾脏替代治疗:第一波16/87(18%)vs 第二波8/128(6%)(p=0.0055)。
  • ICU血管活性药物支持:第一波64/87(74%)vs 第二波51/128(40%)(p<0.001)。

研究设计与关键结果

  • 研究类型:单中心前瞻性队列研究;地点:三级大学医院;人群:第一波341例、第二波695例住院成人COVID-19患者(第二波33例因转院排除,纳入分析662例)。
  • 主要终点30天死亡率:第一波74/341(22%)vs 第二波98/662(15%)(p=0.007)。
  • 中位年龄:第一波68岁(57-80)vs 第二波71岁(60-80)(p=0.15),入院严重程度相似。
  • 病房治疗变化:地塞米松、高流量鼻氧、瑞德西韦使用增加,羟氯喹使用减少(详见management)。
  • ICU转入率:第一波87/341(26%)vs 第二波128/662(19%)(p=0.024);ICU入住时中位SOFA评分:第一波6(3-7)vs 第二波4(3-6)(p=0.02)。
  • ICU中位住院时间:第一波14天(5-27天)vs 第二波6天(3-11天)(p<0.001)。

证据类型、等级与局限

  • 证据类型:单中心前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,两波之间主要治疗变化为使用类固醇、对低氧患者无限制使用高流量鼻氧、ICU拥挤时将患者转至其他地理区域,这些变化与30天死亡率、ICU转入及器官支持减少相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To compare patient management and outcome during the first and second waves of the coronavirus 2019 pandemic.

DESIGN: Single-center prospective cohort study.

SETTING: Tertiary-care University Hospital.

PATIENTS: All adult patients admitted in either the first (from March 15 to May 15, 2020) or second (from October 1 to November 30, 2020) wave of coronavirus disease 2019.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Primary outcome was 30-day mortality. During the second wave of the coronavirus disease 2019 pandemic, 33 patients (4.8%) were transferred due to overcrowding and excluded from analysis. There were 341 (first wave of the coronavirus disease 2019 pandemic) and 695 (second wave of the coronavirus disease 2019 pandemic) coronavirus disease 2019 patients admitted to the hospital, with median age first wave of the coronavirus disease 2019 pandemic as 68 (57-80) and second wave of the coronavirus disease 2019 pandemic as 71 (60-80) (p = 0.15), and similar admission severity. For the first wave of the coronavirus disease 2019 pandemic versus second wave of the coronavirus disease 2019 pandemic, 30-day mortality was 74/341 (22%) and 98/662 (15%) (p = 0.007). In the ward, 11/341 (3.2%) and 404/662 (61%) received dexamethasone (p < 0.001); 6/341 (2%) and 79/662 (12%) received high-flow nasal oxygen (p < 0.0001); 2/341 (0.6%) and 88/662 (13.3%) received remdesivir (p < 0.0001); 249/341 (73%) and 0/662 (0%) received hydroxychloroquine (p < 0.0001); and 87/341 (26%) and 128/662 (19%) (p = 0.024) patients were transferred to ICU. On ICU admission, median Sequential Organ Failure Assessment was 6 (3-7) and 4 (3-6) (p = 0.02). High-flow nasal oxygen was given to 16/87 (18%) and 102/128 (80%) (p < 0.001); 69/87 (79%) and 56/128 (44%) received mechanical ventilation (p < 0.001) with durations 17 days (10-26 d) and 10 days (5-17 d) (p = 0.01). Median ICU length of stay was 14 days (5-27 d) and 6 days (3-11 d) (p < 0.001). Finally, 16/87 (18%) and 8/128 (6%) received renal replacement therapy (p = 0.0055); and 64/87 (74%) and 51/128 (40%) needed vasopressor support (p < 0.001).

CONCLUSIONS: The main therapeutic changes between the first wave of the coronavirus disease 2019 pandemic and the second wave of the coronavirus disease 2019 pandemic were use of steroids, unrestrictive use of high-flow nasal oxygen for hypoxemic patients, and transfer of patients to other geographic areas in the case of ICU overcrowding. These changes were associated with a decrease in 30-day mortality, ICU admission, and organ support.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Lambermont B, Rousseau AF, Seidel L, et al. Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium. Crit Care Explor. 2021. PMID: 34079951. doi:10.1097/CCE.0000000000000438

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。